Held in conjunction with the Oncology Nursing Society 41st Annual Congress
To receive continuing education (CE) credit, you must complete the virtual lecture, CE posttest and activity evaluation at the link below.
Access: Virtual Lecture (synchronized audio and slides)
CE Credit Available Until: February 23, 2018
This activity has been designed to meet the educational needs of nurses involved in the care of patients living with hematologic cancers.
At the conclusion of this program, participants should be able to:
- Explain how the heterogeneous nature of blood cancers dictates treatment and prognosis
- Describe the evolving role of CAR T-cell therapy in treating blood cancers
- Educate patients about participation in a clinical trial
Margaret McCormick, RN, BSN, MA
Lead, Clinical Trial Support Services
The Leukemia & Lymphoma Society
Rye Brook, NY
Brenna Hansen, BSN, RN, OCN®
Research Nurse Specialist
Center for Cancer Research, National Cancer Institute (NCI)
National Institutes of Health
Monica I. Kwari, RN, BSN, CCRP
Research Nurse Supervisor
Department of Leukemia
MD Anderson Cancer Center
Sponsors and Supporters
This activity is supported by independent educational grants from Stemline Therapeutics, Inc., Kite Pharma, Inc., and Novartis Pharmaceuticals Corporation.